Exeliom Biosciences
Microbiome-based immunotherapy company developing live biotherapeutic products that leverage the gut microbiome to enhance cancer immunotherapy responses.
Notes
Exeliom Biosciences is a clinical-stage biotechnology company based in Lyon, France, focused on developing microbiome-based immunotherapies for cancer. The company develops live biotherapeutic products (LBPs) designed to modulate the gut microbiome to enhance the efficacy of cancer immunotherapies.
Research has shown that the composition of the gut microbiome can significantly impact patient responses to cancer immunotherapy, including checkpoint inhibitors. Exeliom's approach aims to optimize the microbiome to improve immunotherapy outcomes in cancer patients.
The company is part of the CE-Ventures portfolio.
Team
- Leadership team available on company website
Additional Research Findings
- Founded in 2016
- Portfolio company of CE-Ventures
- Headquarters: Lyon, France
- Focus on microbiome-based immunotherapy
- Live biotherapeutic products (LBPs)
- Clinical-stage development
- Targets immune enhancement in oncology
- Part of growing microbiome therapeutics space
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| CE-Ventures (Crescent Enterprises) | Sharjah, UAE | generalist | seedseries-a+3 | 4 |